Abstract:Purpose: Nonsmall cell lung cancer (NSCLC) patient radiation therapy (RT) is planned without consideration of spatial heterogeneity in lung function or tumor response. We assessed the dosimetric and clinical feasibility of functional lung avoidance and response-adaptive escalation (FLARE) RT to reduce dose to [99m Tc]MAA-SPECT/CT perfused lung while redistributing an escalated boost dose within [18 F]FDG-PET/CT-defined biological target volumes (BTV). Methods: Eight stage IIB-IIIB NSCLC patients underwent FDG-PET/CT and MAA-SPECT/CT treatment planning scans. Perfused lung objectives were derived from scatter/collimator/attenuation-corrected MAA-SPECT uptake relative to ITV-subtracted lung to maintain < 20 Gy mean lung dose (MLD). Prescriptions included 60 Gy to the planning target volume (PTV) and concomitant boost of 74 Gy mean to biological target volumes (BTV = GTV + PET gradient segmentation) scaled to each BTV voxel by relative FDG-PET SUV. Dose-painting-by-numbers prescriptions were integrated into commercial treatment planning systems via uptake threshold discretization. Dose constraints for lung, heart, cord, and esophagus were defined. FLARE RT plans were optimized with volumetric modulated arc therapy (VMAT), proton pencil beam scanning (PBS) with 3%-3 mm robust optimization, and combination of PBS (avoidance) plus VMAT (escalation). The high boost dose region was evaluated within a standardized SUVpeak structure. FLARE RT plans were compared to reference VMAT plans. Linear regression between radiation dose to BTV and normalized FDG PET SUV at every voxel was conducted, from which Pearson linear correlation coefficients and regression slopes were extracted. Spearman rank correlation coefficients were estimated between radiation dose to lung and normalized SPECT uptake. Dosimetric differences between treatment modalities were evaluated by Friedman nonparametric paired test with multiple sampling correction. Results: No unacceptable violations of PTV and normal tissue objectives were observed in 24 FLARE RT plans. Compared to reference VMAT plans, FLARE VMAT plans achieved a higher mean dose to BTV (73.7 Gy 98195. 61.3 Gy), higher mean dose to SUVpeak (89.7 Gy vs. 60.8 Gy), and lower mean dose to highly perfused lung (7.3 Gy vs. 14.9 Gy). These dosimetric gains came at the expense of higher mean heart dose (9.4 Gy vs. 5.8 Gy) and higher maximum cord dose (50.1 Gy vs. 44.6 Gy) relative to the reference VMAT plans. Between FLARE plans, FLARE VMAT achieved higher dose to the SUVpeak ROI than FLARE PBS (89.7 Gy vs. 79.2 Gy, P = 0.01), while FLARE PBS delivered lower dose to lung than FLARE VMAT (11.9 Gy vs. 15.6 Gy, P < 0.001). Voxelwise linear dose redistribution slope between BTV dose and FDG PET uptake was higher in magnitude for FLARE PBS + VMAT (0.36 Gy per %SUVmax ) compared to FLARE VMAT (0.27 Gy per %SUVmax ) or FLARE PBS alone (0.17 Gy per %SUVmax ). Conclusions: FLARE RT is clinically feasible with VMAT and PBS. A combination of PBS for functional lung avoidance and VMAT for FDG PET dose escalation balanced target and normal tissue objective tradeoffs. These results provide a technical platform for testing of FLARE RT safety and efficacy within a precision radiation oncology trial.

Enhancing targeted doses: Low‐energy photon lipiodol‐enhanced radiotherapy (LEPERT) for liver cancer patients

Gd-Eob-Dtpa-Enhanced Liver Magnetic Resonance Imaging As Image Biomarker for Assessment of Liver Injury after External Beam Radiation Therapy

Lonidamine Liposomes to Enhance Photodynamic and Photothermal Therapy of Hepatocellular Carcinoma by Inhibiting Glycolysis

Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume

Dosimetry of particle radiotherapy for liver cancer adjacent to gastrointestinal tract

Feasibility of using contrast-free quantitative magnetic resonance imaging for liver sparing stereotactic ablative body radiotherapy

Potential Therapeutic Improvements in Prostate Cancer Treatment Using Pencil Beam Scanning Proton Therapy with LETd Optimization and Disease-Specific RBE Models

Investigate Potential Clinical Benefits and Linear Energy Transfer Sparing Utilizing Proton Arc Therapy for Hepatocellular Carcinoma

Enabling Clinical Use of Linear Energy Transfer in Proton Therapy for Head and Neck Cancer -- A Review of Implications for Treatment Planning and Adverse Events Study

Dose averaged linear energy transfer optimization for large sacral chordomas in carbon ion therapy

Optimization of collimator angle combined island blocking with parked gap achieves superior normal tissue sparing in SBRT planning of multiple liver lesions

Lung dose calculation with SPECT/CT for ⁹⁰Yittrium radioembolization of liver cancer

Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy

Technical feasibility of novel immunostimulatory low‐dose radiation for polymetastatic disease with CBCT‐based online adaptive and conventional approaches

Dosimetric advantages of IMPT over IMRT for laser-accelerated proton beams

A model-based risk-minimizing proton treatment planning concept for brain injury prevention in low-grade glioma patients

Phantom study for 90 Y liver radioembolization dosimetry with a long axial field-of-view PET/CT

Translating contrast enhanced computed tomography images to liver radioembolization dose distribution for more comprehensively indicating patients

Clinical Feasibility of Leakage and Transmission Radiation Dosimetry Using Multileaf Collimator of ELEKTA Synergy-S Accelerator During Conventional Radiotherapy

Impact of dose calculation accuracy on inverse linear energy transfer optimization for intensity‐modulated proton therapy

Up modulation of dose‐averaged linear energy transfer by simultaneous integrated boost in carbon‐ion radiotherapy for pancreatic carcinoma